CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC | Publicación